| Literature DB >> 17283624 |
Alexander Rodriguez-Palacios1, Henry R Stämpfli, Todd Duffield, Andrew S Peregrine, Lise A Trotz-Williams, Luis G Arroyo, Jon S Brazier, J Scott Weese.
Abstract
We investigated Clostridium difficile in calves and the similarity between bovine and human C. difficile PCR ribotypes by conducting a case-control study of calves from 102 dairy farms in Canada. Fecal samples from 144 calves with diarrhea and 134 control calves were cultured for C. difficile and tested with an ELISA for C. difficile toxins A and B. C. difficile was isolated from 31 of 278 calves: 11 (7.6%) of 144 with diarrhea and 20 (14.9%) of 134 controls (p = 0.009). Toxins were detected in calf feces from 58 (56.8%) of 102 farms, 57 (39.6%) of 144 calves with diarrhea, and 28 (20.9%) of 134 controls (p = 0.0002). PCR ribotyping of 31 isolates showed 8 distinct patterns; 7 have been identified in humans, 2 of which have been associated with outbreaks of severe disease (PCR types 017 and 027). C. difficile may be associated with calf diarrhea, and cattle may be reservoirs of C. difficile for humans.Entities:
Mesh:
Substances:
Year: 2006 PMID: 17283624 PMCID: PMC3372327 DOI: 10.3201/eid1211.051581
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Estimated odds ratios for a calf to have a positive toxin A/B ELISA result, southern Ontario, Canada, 2004*
| Pairwise comparison | Odds ratio | 95% CI | Adjusted Tukey p values |
|---|---|---|---|
| May vs August† | 3.62 | 1.8–8.3 | 0.007 |
| June vs August† | 3.17 | 1.3–7.7 | 0.029 |
| July vs August† | 2.58 | 1.2–5.5 | 0.038 |
| May vs July | 1.41 | 0.7–2.8 | 0.59 |
| June vs July | 1.23 | 0.6–2.6 | 0.85 |
| May vs June | 1.14 | 0.5–2.6 | 0.95 |
*CI, confidence interval. The number of positive toxin A/B ELISA test results and calves sampled per month was May, 23/57; June, 16/41; July, 34/105; and August, 12/75. August data include 2 observations from September.†Statistically significant.
FigureClostridium difficile PCR ribotypes of bovine origin (dairy calves), Ontario, Canada, 2004. *Calf isolate classified as PCR ribotype 017 at the Anaerobe Reference Laboratory, University Hospital of Wales, Cardiff, United Kingdom. Isolates of human (lane 1), calf (lane 2), and canine (lane 3) origin identified in Ontario are indistinguishable. The first and tenth wells contain 100-bp molecular mass markers.
Clostridium difficile PCR ribotypes and toxin genes of 31 isolates obtained from dairy calves in southern Ontario, Canada, 2004
| Toxigenic classification† | Calf PCR ribotypes* | Subtotal, no. (%) | |||||||
| A-11 | B-89 | C-129 | D-189 | E-257 | F-12 | H-75 | I-157 | ||
| A–B–, | – | – | – | – | – | 1 | – | – | 1 (3.2) |
| A–B–, | – | – | – | – | – | 2 | – | – | 2 (6.5) |
| A+B+, | – | – | 2 | – | 4 | – | 1 | 1 | 8 (25.8) |
| A+B+, | 7 | – | – | 4 | – | – | – | – | 11 (35.5) |
| A–B+, | – | 8 | – | – | – | – | – | – | 8 (25.8) |
| A–B+, | – | 1 | – | – | – | – | – | – | 1 (3.2) |
| Subtotal, no. (%) | 7 (22.6) | 9 (29) | 2 (6.5) | 4 (12.9) | 4 (12.9) | 3 (9.7) | 1 (3.2) | 1 (3.2) | 31 (100) |
| Type of | A (7) | None (9) | None (2) | B (4) | None (4) | A (3) | None (1) | None (1) | |
| Human PCR ribotypes§ | 078 | 017 | 077 | 027 | 014 | 033 | 078 | NS¶ | |
| *By PCR typing method of Bidet et al. ( | |||||||||
MIC50 and MIC90 range and resistance frequencies of 30 bovine Clostridium difficile isolates to 4 antimicrobial drugs by E-test on Muller-Hinton agar after 48 h of incubation*
| Drug | MIC50, μg/mL | MIC90, μg/mL | Range, μg/mL | Resistant isolates, % (no. resistant/no. tested), MIC (μg/mL) | Overrepresented PCR ribotypes (no.) |
|---|---|---|---|---|---|
| Vancomycin | 0.5 | 0.75 | 0.25–1.5 | 0 | 0 |
| Metronidazole | 0.38 | 0.75 | 0.125–2.0 | 0 | 0 |
| Levofloxacin | 32 | 32 | 4 to >32 | 73 (22/30), | B89 (9/9), C129 (2/2), D189 (4/4), other 3 ribotypes (7 isolates) |
| Clindamycin | 16.0 | >256 | 6 to >256 | 73 (22/30), | B89 (9/9), C129 (2/2) |
*The breakpoints used were vancomycin susceptible, <4.0 μg/mL; vancomycin resistant, >32.0 μg/mL; metronidazole susceptible, <8.0 μg/mL; metronidazole resistant, >32.0 μg/mL; clindamycin susceptible, <2.0 μg/mL; clindamycin resistant >8.0 μg/mL; levofloxacin susceptible, <2.0 μg/mL; levofloxacin resistant, >8.0 μg/mL.